La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

SundrugLtd Salute del bilancio

Salute finanziaria criteri di controllo 5/6

SundrugLtd ha un patrimonio netto totale di ¥253.7B e un debito totale di ¥35.0B, che porta il suo rapporto debito/patrimonio netto a 13.8%. Le sue attività totali e le sue passività totali sono rispettivamente ¥416.2B e ¥162.4B. L'EBIT di SundrugLtd è ¥42.0B rendendo il suo rapporto di copertura degli interessi -518.7. Ha liquidità e investimenti a breve termine pari a ¥62.4B.

Informazioni chiave

13.8%

Rapporto debito/patrimonio netto

JP¥35.00b

Debito

Indice di copertura degli interessi	-518.7x
Contanti	JP¥62.35b
Patrimonio netto	JP¥253.75b
Totale passività	JP¥162.44b
Totale attività	JP¥416.18b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Sundrug Co.,Ltd.'s (TSE:9989) Intrinsic Value Is Potentially 31% Above Its Share Price

Sep 25

Analyst Estimates: Here's What Brokers Think Of Sundrug Co.,Ltd. (TSE:9989) After Its Yearly Report

Jun 28

SundrugLtd (TSE:9989) Ticks All The Boxes When It Comes To Earnings Growth

Jun 06

Sundrug Co.,Ltd.'s (TSE:9989) Share Price Not Quite Adding Up

May 11

Be Wary Of SundrugLtd (TSE:9989) And Its Returns On Capital

Apr 10

SundrugLtd (TSE:9989) Will Pay A Dividend Of ¥57.00

Mar 11

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥202.0B ) di 9989 superano le sue passività a breve termine ( ¥118.9B ).

Passività a lungo termine: Le attività a breve termine di 9989 ( ¥202.0B ) superano le sue passività a lungo termine ( ¥43.6B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 9989 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 9989 è aumentato da 0% a 13.8% negli ultimi 5 anni.

Copertura del debito: Il debito di 9989 è ben coperto dal flusso di cassa operativo ( 117.7% ).

Copertura degli interessi: 9989 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

SundrugLtd Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Sundrug Co.,Ltd.'s (TSE:9989) Intrinsic Value Is Potentially 31% Above Its Share Price

Upcoming dividend of JP¥65.00 per share

Sundrug Co.,Ltd.'s (TSE:9989) Business Is Yet to Catch Up With Its Share Price

SundrugLtd's (TSE:9989) Upcoming Dividend Will Be Larger Than Last Year's

Sundrug Co.,Ltd. to Report Q2, 2025 Results on Nov 14, 2024

First quarter 2025 earnings: EPS exceeds analyst expectations

SundrugLtd (TSE:9989) Will Pay A Larger Dividend Than Last Year At ¥65.00

SundrugLtd (TSE:9989) Will Pay A Larger Dividend Than Last Year At ¥65.00

Final dividend increased to JP¥65.00

Analyst Estimates: Here's What Brokers Think Of Sundrug Co.,Ltd. (TSE:9989) After Its Yearly Report

Full year 2024 earnings: EPS exceeds analyst expectations

SundrugLtd (TSE:9989) Ticks All The Boxes When It Comes To Earnings Growth

Sundrug Co.,Ltd. to Report Q1, 2025 Results on Aug 14, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Sundrug Co.,Ltd., Annual General Meeting, Jun 21, 2024

Sundrug Co.,Ltd.'s (TSE:9989) Share Price Not Quite Adding Up

Be Wary Of SundrugLtd (TSE:9989) And Its Returns On Capital

Now 21% overvalued after recent price rise

Upcoming dividend of JP¥57.00 per share

SundrugLtd (TSE:9989) Will Pay A Dividend Of ¥57.00

Now 20% overvalued after recent price rise

Sundrug Co.,Ltd. to Report Fiscal Year 2024 Results on May 15, 2024

Third quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Sundrug Co.,Ltd. to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥57.00 per share at 2.7% yield

Sundrug Co.,Ltd. to Report Q2, 2024 Results on Nov 14, 2023

First quarter 2024 earnings released: EPS: JP¥59.01 (vs JP¥53.86 in 1Q 2023)

Sundrug Co.,Ltd. to Report Q1, 2024 Results on Aug 10, 2023

Sundrug Co.,Ltd., Annual General Meeting, Jun 23, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥50.00 per share at 2.8% yield

Third quarter 2023 earnings released: EPS: JP¥65.36 (vs JP¥56.01 in 3Q 2022)

Sundrug Co.,Ltd. to Report Q3, 2023 Results on Feb 14, 2023

No independent directors

Upcoming dividend of JP¥50.00 per share

Sundrug Co.,Ltd. (TSE:9989) agreed to acquire Daiya, K.K. from Shintaro Ito, Ichiban Co., Ltd and others.

Sundrug Co.,Ltd. to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: EPS: JP¥53.86 (vs JP¥58.18 in 1Q 2022)

Sundrug Co.,Ltd. to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings: EPS misses analyst expectations

Sundrug Co.,Ltd., Annual General Meeting, Jun 25, 2022

No independent directors

Sundrug Co.,Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Upcoming dividend of JP¥35.00 per share

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2022 earnings released: EPS JP¥48.36 (vs JP¥54.98 in 2Q 2021)

Upcoming dividend of JP¥35.00 per share

First quarter 2022 earnings released: EPS JP¥58.18 (vs JP¥60.32 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥217 (vs JP¥203 in FY 2020)

Upcoming dividend of JP¥35.00 per share

Sundrug Co.,Ltd. to Report Fiscal Year 2021 Results on May 14, 2021

New 90-day low: JP¥4,020

Third quarter 2021 earnings released: EPS JP¥61.99 (vs JP¥46.72 in 3Q 2020)

Revenue and earnings miss expectations

New 90-day high: JP¥4,515

Sundrug Co.,Ltd. to Report Q3, 2021 Results on Feb 10, 2021

Sundrug Co.,Ltd. to Report Q2, 2021 Results on Nov 11, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane